Stock LGND LIGAND PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

News Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
79.77 USD -1.95% Intraday chart for Ligand Pharmaceuticals Incorporated +0.21% +11.69%
Apr. 08 Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference CI
Apr. 03 Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
BU
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
AQ
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
BU
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer
CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics
CI
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
BU
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance
MT
Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024
Ligand: Q4 Earnings Snapshot
AQ
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024
CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M
MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66
MT
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
BU
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
AQ
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LGND Stock
  4. News Ligand Pharmaceuticals Incorporated